Billions-of-doses-per-year scale at a fraction of the cost.
Our cultured plant cell-derived version of QS-21 ("cpcQS-21") is produced at >90% purity through a repeatable, environmentally-friendly cGMP process2.
All QS-21 is currently harvested from the bark of Quillaja saponaria1, grown in Chile. Reliance on bark extract results in complex production methods, driving up costs and limiting scalability1,2.
This limits saponin adjuvants to a small number of high-cost vaccines — keeping them out of the pandemic-scale, lower-cost vaccines that could give far more people a more durable, more effective immune response.
SaponiQx replaces the tree with cultured plant cells1. This dramatically lowers the cost, simplifies production, and is highly scalable.
Cultured Quillaja saponaria plant cells, grown from a banked cell line rather than harvested bark.
The cells grow in bioreactors and produce saponins in culture.
Saponins are recovered from the harvested cell biomass.
Chromatography separates QS-21 from related saponins.
Purified QS-21 drug substance, made under cGMP.
January 21st, 2025 · Business Wire
August 12th, 2024 · Business Wire
April 17th, 2024 · Business Wire
February 15th, 2024 · PR Newswire
October 10th, 2023 · Business Wire
August 9th, 2023 · Business Wire
September 10th, 2021 · PR Newswire